Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
April 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Press releases published on March 10, 2025
Choosing Between Braces, Aligners, or Veneers with Dr. Esha Persad, Seminole Florida’s Trusted Dentist
EIN Presswire
·
March 10, 2025
Choosing Between Braces, Aligners, or Veneers with Dr. Esha Persad, Seminole Florida’s Trusted Dentist SEMINOLE, FL, UNITED STATES, March 10, 2025 /EINPresswire.com/ -- When it comes to enhancing your smile, the options can often feel overwhelming. From …
H2Ocean’s Outstanding Participation at the 3rd International Conference on Cancer Research at UTRGV School of Medicine
EIN Presswire
·
March 10, 2025
Sea salt based innovations …
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care
GlobeNewswire
·
March 10, 2025
STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, ( …
Abpro Statement on the Departure of Former CEO Ian Chan
GlobeNewswire
·
March 10, 2025
WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief …
Druid City Vital Care Recognized at Vital Care Infusion Services Annual Conference
GlobeNewswire
·
March 10, 2025
TUSCALOOSA, Ala., March 10, 2025 (GLOBE NEWSWIRE) -- Druid City Vital Care (“Druid City”) was recently recognized at the Vital Care Infusion Services annual conference in Orlando, FL. Three locations -- Tuscaloosa, AL, Tupelo, MS, and North Augusta, SC …
LifeMD Reports Fourth Quarter 2024 Results
GlobeNewswire
·
March 10, 2025
Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60% Adjusted EBITDA increased 78% to $9.0 million Telehealth adjusted EBITDA increased 396% to $5.9 million Full-year cash flow from operations increased 99% to …
Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs
GlobeNewswire
·
March 10, 2025
All resolutions approved by bondholders Closing of Royalty Financing and receipt of first €130 million instalment expected shortly Upon closing of the Royalty Financing, GENFIT will implement the Repurchase of the 2025 OCEANEs and pay the Consent Fee Lille …
Royalty Financing avec HCRx : GENFIT annonce l’approbation de la modification des modalités de ses OCEANEs 2025
GlobeNewswire
·
March 10, 2025
Approbation de toutes les résolutions par les porteurs d’OCEANEs 2025 Closing du Royalty Financing et réception de la première tranche de 130 millions d’euros attendus prochainement À la suite du closing du Royalty Financing, GENFIT procédera au Rachat des …
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025
GlobeNewswire
·
March 10, 2025
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025 Mont-Saint-Guibert, Belgium – Monday, March 10, 2025, 10:05pm CET / 5:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that …
Nyxoah Publiera ses Résultats Financiers du Quatrième Trimestre et de l’Exercice 2024 le 13 Mars 2025
GlobeNewswire
·
March 10, 2025
Nyxoah Publiera ses Résultats Financiers du Quatrième Trimestre et de l’Exercice 2024 le 13 Mars 2025 Mont-Saint-Guibert, Belgique – 10 mars 2025, 22h05 CET / 17h05 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société …
Viemed Healthcare Announces Record 2024 Financial Results
GlobeNewswire
·
March 10, 2025
LAFAYETTE, La., March 10, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its …
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 10, 2025
SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of …
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 10, 2025
– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures – – UDENYCA® net revenue increased 62% year-over-year – – LOQTORZI® net revenue increased 29% quarter-over-quarter – – UDENYCA divestiture on track with Special …
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
GlobeNewswire
·
March 10, 2025
New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients aged six …
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewswire
·
March 10, 2025
— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 — Expansion of PI3Ka franchise to include a pan-mutant …
The Ensign Group to Present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 18, 2025
GlobeNewswire
·
March 10, 2025
SAN JUAN CAPISTRANO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and …
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 10, 2025
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- -- $249.4 million in cash, cash equivalents, and marketable …
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
GlobeNewswire
·
March 10, 2025
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR …
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 10, 2025
Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker Presentation at the American College of Cardiology Meeting …
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire
·
March 10, 2025
RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and …